RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative #breastcancer by Leif Ellisen, @ABhealer108 and colleagues @MGHCancerCenter #antibodydrugconjugate #bcsm
Important exploration of resistance mechanisms for sacituzumab govitecan, important as more ADCs emerge. #bcsm Cc. @weldeiry @bcarneiro7 @Rhodeislandmd
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
New article: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer https://t.co/jWjdSCB8dO #breastcancer #oncology https://t.co/5TVnnnxXF9
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer https://t.co/S0CyeEsYZc
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer | Cancer Discovery https://t.co/v2EIHy1pea
RT @BianchiniGP: Acquired #resistance to #Sacituzumab Govitecan unveiled: parallel genomic alterations of both the antigen (TROP2) and payl…
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
Acquired #resistance to #Sacituzumab Govitecan unveiled: parallel genomic alterations of both the antigen (TROP2) and payload target. @CD_AACR https://t.co/Lv0lV5QRfi
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @NeilVasan: Exiting translational work on biomarkers of resistance to sacituzumab govitecan from @ABhealer108 and Leif Ellisen! Will be…
#bcsm @OncoAlert
Exiting translational work on biomarkers of resistance to sacituzumab govitecan from @ABhealer108 and Leif Ellisen! Will be interesting to see if these mechanisms are conserved for other ADCs.
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts revealed parallel alterations in both mAb (TROP2) & payload (TOP1) targets impairing drug activity Studies on larger numbers n
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in TNBC @ABhealer108 @MGHCancerCenter https://t.co/H78hoTVxge